You are currently viewing Ketamine on the Edge: Mindbloom’s At-Home Injections Spark Debate; UK Eyes Tougher Laws; DEA to Regulate Telehealth Prescribing; Spravato Sales Top $1bn

Ketamine on the Edge: Mindbloom’s At-Home Injections Spark Debate; UK Eyes Tougher Laws; DEA to Regulate Telehealth Prescribing; Spravato Sales Top $1bn

Words by Josh Hardman.

***

We have barely kicked off 2025 and already a handful of ketamine-related news stories have emerged. In this ketamine-focused round-up, we explore:

  • The British government is considering reclassifying ketamine to Class A, alongside drugs like cocaine and heroin, ostensibly due to rising illicit use and health concerns.
  • Janssen’s esketamine nasal spray, Spravato, has become a blockbuster drug with over $1 billion in annual sales and now FDA approval as a monotherapy for treatment-resistant depression. But a recent meta-analysis questions its efficacy, particularly in addressing suicidality.
  • Deep Dive: Mindbloom’s new at-home injectable ketamine program has sparked significant controversy within the psychedelics community, with critics raising safety, ethical, and regulatory concerns—while the company dismisses the backlash as industry-driven opposition and doubles down on its marketing efforts.
  • DEA publishes its proposed telehealth registration scheme for entities looking to prescribe controlled substances remotely, which will have repercussions for at-home ketamine providers.

To continue reading, please log in or join Pα+…

Join Pα+ Today

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.


Already a member? Log In


   Regular Bulletins covering key topics and trends in the psychedelics space
   Regular articles and deep dives across psychedelic research, policy and business
   Interviews with insiders
   Monthly interactive database and commentary on psychedelic patents
   Quick-take analysis of major developments
   A Library of primers and explainers
   Access to our full back catalogue


Learn more about Pα+